-
A new cost effective vaccine against rotavirus
biospectrumasia
March 28, 2017
A new vaccine called BRV-PV against rotavirus is being tested.
-
Ferrier Research Institute and BCFNZ to create new breast cancer vaccine
pharmaceutical-technology
March 23, 2017
Victoria University of Wellington's Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ) ...
-
GSK starts $175M plant to boost production of vaccine star Bexsero
fiercepharma
March 23, 2017
Vaccines have been one of the financial bright spots for GlaxoSmithKline and Bexsero, which it picked up in its asset swap with Novartis, has had stellar sales. To boost both, GSK is building a $175 million plant in Germany so it can expand production of
-
GeoVax pushes ahead in Zika vaccine realm with promising preclinical data
fiercepharma
March 22, 2017
A new Zika vaccine candidate by GeoVax showed promise in preclinical tests on mice, and the company believes it could become “the best solution” to the disease.
-
SutroVax reels in $64M with plans to take on $7B pneumococcal vaccine market
fiercepharma
March 22, 2017
Armed with $64 million in new venture funding, San Francisco’s SutroVax is setting out to challenge the world’s biggest target in vaccines, Pfizer’s superstar pneumococcal shot Prevnar 13.
-
PharmaJet partners with Serum to launch needle-free MMR vaccine
europeanpharmaceuticalreview
March 17, 2017
Needle-free injection technology company PharmaJet has partnered with Serum Institute of India, one of the world’s largest vaccine manufacturers, to commercialise needle-free delivery of the MMR vaccine using the Stratis 0.5ml needle-free injection system
-
GSK submits application to FDA for expanded indication of influenza vaccine
pharmaceutical-technology
March 17, 2017
UK's GlaxoSmithKline (GSK) has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for expanded indication of its influenza vaccine, Fluarix Quadrivalent.
-
Zydus Cadila to launch influenza fighting vaccine in India
financialexpress
February 27, 2017
The vaccine provides protection from four influenza viruses — H1N1, H3N2, Type B (Brisbane)
-
Updated Phase I Data show Bavarian Nordic's vaccine candidate induces broad and durable immune respo
cphi-online
February 27, 2017
Antibody levels maintained against multiple targets 6 months post vaccination.
-
Sanaria works to tweak malaria vaccine dosing after an 'encouraging' African trial
fiercepharma
February 22, 2017
Sanaria’s malaria vaccine posted another positive clinical result as it provided significant protection for many healthy adults in a phase 1 study carried out in Mali, but a notable gap compared with results from U.S. studies calls for scientists to furth